RxDoctor Payments Data

Renee Roth

Acute Care · Dayton, OHNPI 1295975266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,242 and has fallen 84.7% since, to $495 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,561in general payments, 2019–2025

Across 421 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$705
  • Novartis$559
  • Johnson & Johnson$539
  • Daiichi Sankyo Inc.$499
  • Exelixis Inc.$394
  • Bristol Myers Squibb$393
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,48399%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck35$705
Novartis33$559
Johnson & Johnson27$539
Daiichi Sankyo Inc.26$499
Exelixis Inc.3$394
Bristol Myers Squibb23$393
Lilly USA, LLC16$382
AbbVie19$375
Incyte Corporation16$314
Pharmacyclics LLC, An Abbvie Company13$312
AstraZeneca(2 entities)15$293
Sanofi11$291
Takeda Pharmaceuticals U.S.A., Inc.10$209
Tersera Therapeutics LLC9$190
GSK10$190
Eisai Inc.10$188
Jazz Pharmaceuticals Inc.6$176
Genentech USA, Inc.13$161
Amgen9$143
Bayer8$136
Regeneron Healthcare Solutions, Inc.7$134
Pfizer7$126
E.r. Squibb & Sons, L.L.C.5$115
Beigene USA, Inc.6$115
Gilead(2 entities)7$112
ADC Therapeutics America, Inc.6$107
Stemline Therapeutics Inc.4$93
Ipsen Biopharmaceuticals, Inc5$91
Kyowa Kirin, Inc.5$90
Seagen Inc.4$83
Astellas Pharma US Inc4$78
Genmab U.S., Inc.3$74
Servier Pharmaceuticals LLC4$73
Blueprint Medicines Corporation4$63
Rigel Pharmaceuticals, Inc.4$60
Sumitomo Pharma America, Inc.2$57
Foundation Medicine, Inc.2$50
Morphosys, US Inc.2$48
Adaptive Biotechnologies Corporation2$45
Pharmaessentia USA Corporation2$42
Cumberland Pharmaceuticals, Inc.2$40
Pharmacosmos Therapeutics Inc.2$37
Karyopharm Therapeutics Inc.2$36
Sobi, Inc2$33
Sun Pharmaceutical Industries Inc.1$30
Boehringer Ingelheim1$27
Recordati_rare_diseases_inc.1$25
Fresenius Kabi USA, LLC1$24
AVEO Pharmaceuticals, Inc.1$21
Array Biopharma Inc1$20
Deciphera Pharmaceuticals Inc.1$20
Fennec Pharmaceuticals, Inc.1$19
Menarini Silicon Biosystems, Inc.1$18
Amneal Pharmaceuticals LLC1$18
Taiho Oncology, Inc.1$17
Immunocore Limited1$17
Dendreon Pharmaceuticals LLC1$16
Springworks Therapeutics, Inc.1$15
G1 Therapeutics, Inc.1$15
Puma Biotechnology, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,561 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$229,663
Medicare patients
182
Services billed
13,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib20$288,435
IbrancePalbociclib11$167,052
EliquisApixaban110$75,690
Exemestane39$5,778
Ondansetron Hcl55$3,349
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$2,885
Fentanyl21$2,807
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen49$2,239
Morphine Sulfate ErMorphine Sulfate33$1,421
Oxycodone Hcl41$1,067
Dexamethasone49$917
Potassium Chloride56$800
Prochlorperazine Maleate60$797
Gabapentin80$637
Albuterol Sulfate HfaAlbuterol Sulfate19$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$115$288,43520 claims
PfizerIbrance, Eliquis$126$242,743121 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$21930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.

Other acute care in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →